Portal de Periódicos da CAPES

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

2019; American Association for Cancer Research; Volume: 25; Issue: 14 Linguagem: Inglês

10.1158/1078-0432.ccr-18-3275

1557-3265

Dana Pru̇ková, Ladislav Anděra, Zuzana Nahácka, Jana Karolová, Michael Svatoň, Magdalena Klánová, Ondřej Havránek, J. Soukup, Karla Svobodová, Zuzana Zemanová, Diana Tušková, Eva Pokorná, Karel Helman, Kristina Forsterová, Mariana Pacheco‐Blanco, Petra Vočková, Adéla Berková, Eva Froňková, Marek Trněný, Pavel Klener,

Cancer-related gene regulation

Abstract Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over)expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of venetoclax resistance in MCL cells and tested strategies to overcome it. Experimental Design: We confirmed key roles of proapoptotic proteins BIM and NOXA in mediating venetoclax-induced cell death in MCL. Both BIM and NOXA are, however, differentially expressed in cell lines compared with primary cells. First, NOXA protein is significantly overexpressed in most MCL cell lines. Second, deletions of BIM gene harbored by three commonly used MCL cell lines (JEKO-1, MINO, and Z138) were not found by array comparative genomic hybridization using a validation set of 24 primary MCL samples. Results: We demonstrated that MCL1 and NOXA play important roles in mediating resistance to venetoclax. Consequently, we tested an experimental treatment strategy based on cotargeting BCL2 with venetoclax and MCL1 with a highly specific small-molecule MCL1 inhibitor S63845. The combination of venetoclax and S63845 demonstrated synthetic lethality in vivo on a panel of five patient-derived xenografts established from patients with relapsed MCL with adverse cytogenetics. Conclusions: Our data strongly support investigation of venetoclax in combination with S63845 as an innovative treatment strategy for chemoresistant MCL patients with adverse cytogenetics in the clinical grounds.